/**/ RNS Number : 9294R IQ-AI Limited 11 July 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Announces Channel Partnership IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution
/**/ RNS Number : 3069N IQ-AI Limited 31 May 2022 31 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022: Imaging Biometrics, LLC (IB),
Milwaukee – 7 March 2022: Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual
Milwaukee – 1 October 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors.
Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced it has been awarded a European Patent for “Multiparameter Perfusion Imaging
Elm Grove, WI, June 23, 2021 – IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams. A zero-dose exam potentially offers remarkable benefits which include a more comfortable patient experience, more productive radiology departments,
Birmingham, Ala. Nov. 16, 2020 – AI Metrics, LLC, a medical imaging startup focused on leveraging artificial intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the company’s LSN (Liver Surface Nodularity) module. This first FDA clearance represents a significant milestone for AI Metrics, where
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.